Payment overview · 2025
General Payments
$381.18
17 reported records · 11 companies
Healthcare provider profile · identity verified
Michael E Belete, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MILWAUKEE, WI · NPI 1811075328
Verified facts
What the public records show
CMS Open Payments records show Michael E Belete, MD received $381.18 in general payments during 2025 across 17 reported records.
ABBVIE INC. accounted for 20.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Linzess, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $77.42 | 20.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $75.23 | 19.7% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $41.53 | 10.9% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.84 | 9.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.26 | 9.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.38 | 6.9% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $21.23 | 5.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.00 | 5.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.23 | 4.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.60 | 4.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.46 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $381.18 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $47.68 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $34.84 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.74 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.74 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $26.38 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 55 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
65 | 14 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 671 | 181 |
| Amlodipine Besylate | Amlodipine Besylate | 659 | 170 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 407 | 81 |
| Losartan Potassium | Losartan Potassium | 350 | 81 |
| Gabapentin | Gabapentin | 213 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 203 | 54 |
| Trulicity | Dulaglutide | 194 | 26 |
| Lisinopril | Lisinopril | 185 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 181 | 42 |
| Omeprazole | Omeprazole | 177 | 50 |
| Metformin Hcl Er | Metformin Hcl | 163 | 39 |
| Carvedilol | Carvedilol | 155 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 151 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 134 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 124 | 32 |
| Metformin Hcl | Metformin Hcl | 123 | 33 |
| Simvastatin | Simvastatin | 106 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 98 | 26 |
| Furosemide | Furosemide | 97 | 27 |
| Potassium Chloride | Potassium Chloride | 96 | 26 |
| Allopurinol | Allopurinol | 95 | 23 |
| Pregabalin | Pregabalin | 93 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 20 |
| Jardiance | Empagliflozin | 89 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 65 | 14 |
| Levetiracetam | Levetiracetam | 64 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 15 |
| Mirtazapine | Mirtazapine | 63 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 62 | 16 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 60 | 17 |
| Baclofen | Baclofen | 59 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 58 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 57 | suppressed |
| Ibuprofen | Ibuprofen | 55 | 18 |
| Linzess | Linaclotide | 55 | 11 |
| Levothyroxine Sodium | Levothyroxine Sodium | 50 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 45 | 13 |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 40 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | suppressed |
| Ozempic | Semaglutide | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Eliquis | Apixaban | 37 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | 13 |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Famotidine | Famotidine | 35 | suppressed |
| Febuxostat | Febuxostat | 35 | suppressed |
| Meloxicam | Meloxicam | 34 | 11 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 11 |
| Hydrocortisone | Hydrocortisone | 28 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Lubiprostone | Lubiprostone | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | 11 |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| True Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 18 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $381.18 · 17 records | ABBVIE INC. | AIRSUPRA, CAMZYOS, CAPLYTA, ELIQUIS, FANAPT, Kerendia, LINZESS, NEFFY, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, The Cologuard Plus Collection Kit, UBRELVY, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error